Literature DB >> 12599073

CC chemokine receptor 5 genotype and susceptibility to transmission of human immunodeficiency virus type 1 in women.

Sean Philpott1, Barbara Weiser, Patrick Tarwater, Sten H Vermund, Cynthia A Kleeberger, Stephen J Gange, Kathryn Anastos, Mardge Cohen, Ruth M Greenblatt, Andrea Kovacs, Howard Minkoff, Mary A Young, Paolo Miotti, Michelle Dupuis, Chih-Hsiung Chen, Harold Burger.   

Abstract

The human gene for CC chemokine receptor 5, a coreceptor for human immunodeficiency virus type 1 (HIV-1), affects susceptibility to infection. Most studies of predominantly male cohorts found that individuals carrying a homozygous deleted form of the gene, Delta 32, were protected against transmission, but protection did not extend to Delta 32 heterozygotes. The role played by this mutation in HIV-1 transmission to women was studied in 2605 participants in the Women's Interagency HIV Study. The Delta 32 gene frequency was 0.026 for HIV-1-seropositive women and 0.040 for HIV-1-seronegative women, and statistical analyses showed that Delta 32 heterozygotes were significantly less likely to be infected (odds ratio, 0.63 [95% confidence interval, 0.44-0.90]). The CCR5 Delta 32 heterozygous genotype may confer partial protection against HIV-1 infection in women. Because Delta 32 is rare in Africans and Asians, it seems plausible that differential genetic susceptibility, in addition to social and behavioral factors, may contribute to the rapid heterosexual spread of HIV-1 in Africa and Asia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12599073      PMCID: PMC3319124          DOI: 10.1086/367995

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda.

Authors:  R H Gray; M J Wawer; R Brookmeyer; N K Sewankambo; D Serwadda; F Wabwire-Mangen; T Lutalo; X Li; T vanCott; T C Quinn
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

2.  The coreceptor mutation CCR5Delta32 influences the dynamics of HIV epidemics and is selected for by HIV.

Authors:  A D Sullivan; J Wigginton; D Kirschner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

3.  Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis.

Authors:  A H Kral; R N Bluthenthal; J Lorvick; L Gee; P Bacchetti; B R Edlin
Journal:  Lancet       Date:  2001-05-05       Impact factor: 79.321

4.  Gender differences in HIV-1 diversity at time of infection.

Authors:  E M Long; H L Martin; J K Kreiss; S M Rainwater; L Lavreys; D J Jackson; J Rakwar; K Mandaliya; J Overbaugh
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

5.  Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa.

Authors:  S A Allen; R Musonda; S Trask; B H Hahn; H Weiss; J Mulenga; F Kasolo; S H Vermund; G M Aldrovandi
Journal:  AIDS Res Hum Retroviruses       Date:  2001-07-01       Impact factor: 2.205

6.  Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective.

Authors:  S A Strathdee; N Galai; M Safaiean; D D Celentano; D Vlahov; L Johnson; K E Nelson
Journal:  Arch Intern Med       Date:  2001-05-28

7.  Coexpression of CCR5 and IL-2 in human genital but not blood T cells: implications for the ontogeny of the CCR5+ Th1 phenotype.

Authors:  F Hladik; G Lentz; E Delpit; A McElroy; M J McElrath
Journal:  J Immunol       Date:  1999-08-15       Impact factor: 5.422

8.  Accuracy of self-reports of acquired immunodeficiency syndrome and acquired immunodeficiency syndrome-related conditions in women.

Authors:  N A Hessol; S Schwarcz; N Ameli; G Oliver; R M Greenblatt
Journal:  Am J Epidemiol       Date:  2001-06-01       Impact factor: 4.897

9.  Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection.

Authors:  M Marmor; H W Sheppard; D Donnell; S Bozeman; C Celum; S Buchbinder; B Koblin; G R Seage
Journal:  J Acquir Immune Defic Syndr       Date:  2001-08-15       Impact factor: 3.731

10.  Association of race and gender with HIV-1 RNA levels and immunologic progression.

Authors:  K Anastos; S J Gange; B Lau; B Weiser; R Detels; J V Giorgi; J B Margolick; M Cohen; J Phair; S Melnick; C R Rinaldo; A Kovacs; A Levine; S Landesman; M Young; A Muñoz; R M Greenblatt
Journal:  J Acquir Immune Defic Syndr       Date:  2000-07-01       Impact factor: 3.731

View more
  14 in total

Review 1.  The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench.

Authors:  Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

Review 2.  Resistance to HIV infection.

Authors:  M Marmor; K Hertzmark; S M Thomas; P N Halkitis; M Vogler
Journal:  J Urban Health       Date:  2006-01       Impact factor: 3.671

3.  Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination.

Authors:  Sean Philpott; Harold Burger; Christos Tsoukas; Brian Foley; Kathryn Anastos; Christina Kitchen; Barbara Weiser
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 4.  How does HIV-1 infect a susceptible human cell?: Current thinking.

Authors:  Ali A Al-Jabri
Journal:  J Sci Res Med Sci       Date:  2003-08

Review 5.  Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.

Authors:  Peter L Anderson; Jennifer J Kiser; Edward M Gardner; Joseph E Rower; Amie Meditz; Robert M Grant
Journal:  J Antimicrob Chemother       Date:  2010-11-30       Impact factor: 5.790

6.  HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation.

Authors:  Kimdar Sherefa Kemal; Brian Foley; Harold Burger; Kathryn Anastos; Howard Minkoff; Christina Kitchen; Sean M Philpott; Wei Gao; Esther Robison; Susan Holman; Carolyn Dehner; Suzanne Beck; William A Meyer; Alan Landay; Andrea Kovacs; James Bremer; Barbara Weiser
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-13       Impact factor: 11.205

7.  CCR2 genotype and disease progression in a treated population of HIV type 1-infected women.

Authors:  Sean Philpott; Harold Burger; Patrick M Tarwater; Ming Lu; Stephen J Gange; Kathryn Anastos; Mardge Cohen; Ruth M Greenblatt; Andrea Kovacs; Howard Minkoff; Mary Young; Paolo Miotti; Michelle Dupuis; Barbara Weiser
Journal:  Clin Infect Dis       Date:  2004-08-27       Impact factor: 9.079

8.  Risk of all-cause mortality in HIV infected patients is associated with clinical, immunologic predictors and the CCR5 Δ32 deletion.

Authors:  Milosz Parczewski; Dorota Bander; Magdalena Leszczyszyn-Pynka; Anna Urbanska; Mariusz Kaczmarczyk; Andrzej Ciechanowicz; Anna Boron-Kaczmarska
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

9.  Effect of CCR5-Δ32 heterozygosity on HIV-1 susceptibility: a meta-analysis.

Authors:  Sijie Liu; Chuijin Kong; Jie Wu; Hao Ying; Huanzhang Zhu
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

10.  Partial protective effect of CCR5-Delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals.

Authors:  Enrico M Trecarichi; Mario Tumbarello; Katleen de Gaetano Donati; Enrica Tamburrini; Roberto Cauda; Christina Brahe; Francesco D Tiziano
Journal:  AIDS Res Ther       Date:  2006-09-25       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.